About this Research Topic
In the last decades, the success of cancer immunotherapy has considerably changed our understanding of cancer biology and brought patients a major improvement in survival. In hematological malignancies (HM), immune checkpoint inhibitors (ICIs) have shown promising therapeutic outcomes in some cancer types.
However, some HMs such as acute myeloid leukemia (AML) still remain a “cold tumor”; others may initially respond to ICIs, but eventually develop resistance and become a cold tumor. Hence, there is a pressing need to develop an effective therapy to convert an immune-cold tumor into a hot one. Herein, we will discuss emerging therapeutic opportunities that could be potentially translated into treatment options for patients with these immune-cold HMs.
We welcome the submission of high-quality Systematic Reviews, Mini Reviews, Reviews, and Original Research including but not limited to, the following areas:
-Molecular understanding of AML or other tumors not sensitive to ICIs
-Effective therapies or strategies for sensitizing tumors to immune checkpoint inhibitors
-Predictive biomarkers that could provide clinical benefit with immunotherapy and its potential mechanisms
-Targeted drugs combined with ICIs that provide a synergistic effect leading to response improvement
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
However, some HMs such as acute myeloid leukemia (AML) still remain a “cold tumor”; others may initially respond to ICIs, but eventually develop resistance and become a cold tumor. Hence, there is a pressing need to develop an effective therapy to convert an immune-cold tumor into a hot one. Herein, we will discuss emerging therapeutic opportunities that could be potentially translated into treatment options for patients with these immune-cold HMs.
We welcome the submission of high-quality Systematic Reviews, Mini Reviews, Reviews, and Original Research including but not limited to, the following areas:
-Molecular understanding of AML or other tumors not sensitive to ICIs
-Effective therapies or strategies for sensitizing tumors to immune checkpoint inhibitors
-Predictive biomarkers that could provide clinical benefit with immunotherapy and its potential mechanisms
-Targeted drugs combined with ICIs that provide a synergistic effect leading to response improvement
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: immune checkpoint inhibitors, T cells, Cold tumor, Immunotherapy, Macrophage
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
